clinical trial · NCT05835895
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Osteoarthritis, KneeOsteo Arthritis KneeKnee OsteoarthritisGNSC-001transient immune-modulationtransient immune-modulationPlacebo
brief summary
The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.
started
Jun 12, 2023
primary completion
Apr 8, 2025
completion
May 1, 2029
last updated
Aug 1, 2025
official title
A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol